The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of XNW27011, a Claudin 18.2 targeting antibody drug conjugate with topoisomerase 1 inhibitor payload, in patients with Claudin 18.2 positive gastric/gastroesophageal junction cancer: Results from ongoing phase I/II study.
 
Jinming Yu
Employment - Evopoint Biosciences
Leadership - Evopoint Biosciences
Stock and Other Ownership Interests - Evopoint Biosciences
 
Yuping Sun
No Relationships to Disclose
 
Tianshu Liu
No Relationships to Disclose
 
Zengqing Guo
No Relationships to Disclose
 
Jieer Ying
No Relationships to Disclose
 
Meili Sun
No Relationships to Disclose
 
Qing Wen
No Relationships to Disclose
 
Zhenyang Liu
No Relationships to Disclose
 
Yongchang Zhang
No Relationships to Disclose
 
Jin Xia
No Relationships to Disclose
 
Fangling Ning
No Relationships to Disclose
 
Lixin Wan
No Relationships to Disclose
 
Jingdong Zhang
No Relationships to Disclose
 
Ting Deng
No Relationships to Disclose
 
Jun Zhao
No Relationships to Disclose
 
Jianguo Li
Employment - Evopoint Biosciences
Leadership - Evopoint Biosciences
Stock and Other Ownership Interests - Evopoint Biosciences
 
Qifeng Shi
Employment - Evopoint Biosciences Co., Ltd
Stock and Other Ownership Interests - Evopoint Biosciences Co., Ltd
 
Hui Zhao
Employment - Evopoint Biosciences
Stock and Other Ownership Interests - Evopoint Biosciences Co., Ltd